Associated Genetic Biomarkers


NCI Definition: A non-Hodgkin lymphoma with an aggressive clinical course. Representative examples include Burkitt lymphoma, mantle cell lymphoma, and angioimmunoblastic T-cell lymphoma. [1]

Aggressive non-hodgkin lymphomas most frequently harbor alterations in TET2, ATM, TP53, DNMT3A, and IDH2 [2].

Most Commonly Altered Genes in Aggressive Non-Hodgkin Lymphoma

TET2 Mutation, TET2 Frameshift, ATM Mutation, TP53 Mutation, and TET2 Nonsense are the most common alterations in aggressive non-hodgkin lymphoma [2].

Top Alterations in Aggressive Non-Hodgkin Lymphoma

Disease Details

Non-Hodgkin Lymphoma by Clinical Course
Enteropathy-Associated T-Cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, B-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma, Burkitt Lymphoma, Grade 3 Follicular Lymphoma, Mantle Cell Lymphoma, Sezary Syndrome, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Anaplastic Large Cell Lymphoma, ALK-Negative, Hepatosplenic T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Burkitt-Like Lymphoma with 11q Aberration, T-Cell Lymphoblastic Lymphoma, Peripheral T-Cell Lymphoma, and Nasal Type Extranodal NK/T-Cell Lymphoma


1. National Cancer Institute. NCI Thesaurus Version 18.11d. [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.